Xantos Biomedicine and QIAGEN AnnounceCo-Marketing Agreement for RNAi Library with High-Content Cellular Screening System
Xantos Biomedicine AG and QIAGEN N.V. announced their partnership for co-marketing QIAGEN's proprietary TOM-amidite chemistry based genome-wide RNAi products with Xantos' automated cell-based screening platform, XantoScreen(TM). By combining the capabilities of both companies' platforms customers will be able to rapidly perform gene analysis and unravel the function and role of genes that are relevant to their area of interest.
Xantos provides XantoScreen(TM) for the discovery and functional validation of novel targets on a genome-wide basis. The system enables high throughput and automated cDNA transfection studies (over expression of genes) or RNAi (gene silencing) to be carried out rapidly. This powerful system can be customized to a range of high content cellular screening assays and enables individual cDNAs, RNAi molecules or proteins to be studied in combination with or without inhibitory molecules, to identify and validate targets, ligands, receptors, compounds or pathways.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Emil_du_Bois-Reymond
Plasticell announces grant of fundamental CombiCult patents in USA and Japan
Novel paradigm in drug development - Understanding resistance mechanisms to targeted protein degradation
Gene Logic and deSciner Enter into a Partnership to Create 'Genomics Gateway'
VTT printed haemoglobin test on paper: Bioactivity presents new opportunities for paper

Fast and cheap low-tech method to test for the presence of any DNA sequence

ABB Utility Automation GmbH - Minden, Germany

Insects’ sense of smell gives insight into better repellent design and drug screening
